<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04659057</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU R 110/2020</org_study_id>
    <nct_id>NCT04659057</nct_id>
  </id_info>
  <brief_title>Nebulized Lidocaine, Dexmedetomedine and Their Combination in Direct Laryngoscopy Surgery</brief_title>
  <official_title>Effect of Nebulized Lidocaine, Dexmedetomedine and Their Combination on Haemodynamics During Direct Laryngoscopy Surgery. A Randomized Controlled Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Direct laryngoscopy (DL) procedure is typically done under general anaesthesia as a day case.&#xD;
      It is a short but irritating.Various drugs and drug combinations have been used to attenuate&#xD;
      stress response to DL.Administrating nebulized form of drugs can be effective with less&#xD;
      systemic side effects. The primary outcome of this study is to compare the effect of&#xD;
      premedication with nebulized lidocaine, dexmedetomidine, combination of both to placebo on&#xD;
      haemodynamic response during DL procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be transferred to the induction room 30 min prior to surgery. Standard monitors&#xD;
      will be applied [pulse oximetry, non invasive blood pressure (NIBP) and electrocardiogram&#xD;
      (ECG)]. Basal HR, systolic (SBP), diastolic (DBP) and mean arterial blood pressure (MAP) will&#xD;
      be recorded. An intravenous 22-G cannula will be inserted, and all patients will be&#xD;
      pre-medicated with intravenous midazolam 0.02 mg/kg, granisetrone 2mg and ranitidine 30 mg.&#xD;
&#xD;
      Patients will then be randomly and evenly allocated to one of 4 groups (45 patients each).&#xD;
&#xD;
      Nebulized solutions will be prepared by a pharmacist not participating in the study.&#xD;
      Nebulization will be done with 100% oxygen (10 L/min) through facemask attached to a&#xD;
      nebulizer. Patients will be asked to breath normally. Nebulization will continue till the&#xD;
      solution in the nebulizer is all aerosolized.&#xD;
&#xD;
      Upon arrival to the operating room, routine monitors will be applied in addition to&#xD;
      neuromuscular monitor and end tidal CO2 (ETCO2). General anaesthesia will be induced, after 5&#xD;
      min of preoxygenation, by intravenous fentanyl 1 μg/kg, propofol 1.5-2 mg/kg titrated to a&#xD;
      loss of verbal response and rocuronium 1 mg/kg to facilitate endotracheal intubation.&#xD;
      Mackintosh laryngoscope will be introduced when train of four (TOF) count reaches 1. High&#xD;
      volume-low pressure endotracheal tube (size 5-5.5) will be inserted by senior&#xD;
      anaesthesiologist. HR, SBP, DBP and MAP will be recorded immediately after intubation.&#xD;
&#xD;
      Anaesthesia will be maintained by sevoflurane 2-3% in oxygen to air ratio 1:1. Rocuronium 0.1&#xD;
      mg/kg when required. Positive pressure ventilation will be set to maintain ETCO2 30-35 mmHg.&#xD;
&#xD;
      SBP, DBP, MAP and HR will be recorded on arrival to the induction room (baseline), after&#xD;
      endotracheal intubation, and then every 5 min throughout the surgery.&#xD;
&#xD;
      In case of hypertension (defined as SBP &gt; 140 mmHg, DBP &gt;90 mmHg or MAP 20% higher than&#xD;
      baseline) and/or tachycardia (defined as HR 20% higher than baseline), boluses fentanyl 0.5&#xD;
      μg/kg will be given with a maximum dose of 2 μg/Kg. If hypertension and/or tachycardia&#xD;
      continue after reaching the maximum dose of fentanyl, loading dose of esmolol 500 μg/Kg will&#xD;
      be started, followed by infusion of 100-300 μg/kg/min. The use and total dose of esmolol will&#xD;
      be recorded.&#xD;
&#xD;
      In cases of significant hypotension (defined as mean blood pressure &lt; 70 mmHg), the patient&#xD;
      will be treated initially with an intravenous (IV) fluid bolus of10 mL/kg normal saline, and&#xD;
      if the condition persists, the patient will given 0.1-0.3 mg/kg IV ephedrine, which will be&#xD;
      repeated every 3-5 minutes until the blood pressure is normalized. Significant bradycardia&#xD;
      (defined as heart rate &lt; 60 beat/min) will be treated, when needed, with IV atropine 0.02&#xD;
      mg/kg.&#xD;
&#xD;
      At the conclusion of surgery, sevoflurane will be discontinued and patients will inhale 100%&#xD;
      O2. After return of spontaneous breathing, residual neuromuscular block will be reversed with&#xD;
      intravenous neostigmine 0.05 mg/kg and glycopyrolate 0.01 mg/kg. Extubation will be done when&#xD;
      the patient starts to show purposeful movements.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2020</start_date>
  <completion_date type="Actual">July 11, 2021</completion_date>
  <primary_completion_date type="Actual">July 11, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Every 5 minutes for 30-60minutes</time_frame>
    <description>Heart rate in beats/min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>Every 5 minutes for 30-60 minutes</time_frame>
    <description>Systolic blood pressure in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>Every 5 minutes for 30-60 minutes</time_frame>
    <description>Diastolic blood pressure in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean arterial pressure</measure>
    <time_frame>Every 5 min for 30-60 minutes</time_frame>
    <description>Mean arterial pressure in mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total fentanyl and esmolol consumption</measure>
    <time_frame>For 30-60 minutes</time_frame>
    <description>The total dose of fentanyl and/or esmolol consumed by each patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recovery time</measure>
    <time_frame>5- 15 minutes</time_frame>
    <description>The time from discontinuation of anaesthetic drugs until response to verbal commands</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Hemodynamic Instability</condition>
  <arm_group>
    <arm_group_label>Group L</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lidocaine group; 45 randomly assigned patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Demedetomidine group; 45 randomly assigned patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group DL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combined lidocaine and dexmedetomidine group. 45 randomly assigned patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group; 45 randomly assigned patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized Lidocaine</intervention_name>
    <description>will receive nebulized lidocaine 2%, 1 mg/kg with a maximum dose of 100 mg (5 ml).</description>
    <arm_group_label>Group L</arm_group_label>
    <other_name>Lidocaine group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized dexmedetomidine</intervention_name>
    <description>will receive nebulized dexmedetomidine (1 μg/kg diluted in 5 ml of saline 0.9%).</description>
    <arm_group_label>Group D</arm_group_label>
    <other_name>Dexmedetomidine group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized lidocaine and dexmedetomidine</intervention_name>
    <description>will receive nebulized lidocaine 2% (0.5 mg/kg) and dexmedetomidine 0.5 μg/kg dexmedetomidine in 5 ml of saline 0.9%.</description>
    <arm_group_label>Group DL</arm_group_label>
    <other_name>Combined lidocaine and dexmedetomidine group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>will receive nebulized saline 0.9% (5 ml) as control group.</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>Control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA I-III patients admitted for DL surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled hypertension (MAP &gt; 100 mmHg) or ischaemic heart disease.&#xD;
&#xD;
          -  End stage renal impairment.&#xD;
&#xD;
          -  Chronic drug or alcohol abuse.&#xD;
&#xD;
          -  Predicted difficult airway, laryngoscopy and intubation time &gt; 30 sec, more than one&#xD;
             attempt of intubation.&#xD;
&#xD;
          -  Morbid obesity (BMI &gt; 30).&#xD;
&#xD;
          -  Known allergy to the drugs used.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hala S El-Ozairy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <state>Cairo Governorate</state>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ain Shams University Hospitals</name>
      <address>
        <city>Cairo</city>
        <zip>11588</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>July 11, 2021</last_update_submitted>
  <last_update_submitted_qc>July 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Hala Salah El-Din El-Ozairy, MD</investigator_full_name>
    <investigator_title>Lecturer of Anaesthesia, ICU and Pain management, Faculty of Medicine, Ain Shams University</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

